Efficacy, safety, and current applications of brimonidine

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 795-799

  Fudemberg, Scott J ^a   Batiste, Corey ^b   Katz, L Jay ^a  

^a WILLS EYE HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

adrenergic agonists; 2 adrenergic agonists; 5 bromo 6 (2 imidazolidinylideneamino) quinoxaline L tartrate; Alphagan ; Alphagan P; Brimonidine; Brimonidine purite; Brimonidine tartrate; Combigan ; Fixed combination; Glaucoma; Ocular hypertension

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; APRACLONIDINE; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; COMBIGAN; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; PHYSOSTIGMINE; PILOCARPINE; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST; UNCLASSIFIED DRUG;

APNEA; AQUEOUS HUMOR FLOW; ARTICLE; BLEPHARITIS; BLURRED VISION; BRADYCARDIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; CYANOSIS; DERMATITIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; ECTROPION; FATIGUE; GLAUCOMA; HEADACHE; HEART RATE; HUMAN; HYPEREMIA; HYPOTENSION; HYPOVENTILATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LETHARGY; MONOTHERAPY; MUSCLE HYPOTONIA; NEUROLOGIC DISEASE; NONHUMAN; OPEN ANGLE GLAUCOMA; RECEPTOR UPREGULATION; SIDE EFFECT; TACHYPHYLAXIS; TRABECULOPLASTY; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; QUINOXALINES; TIMOLOL; TREATMENT OUTCOME;

EID: 57049095460     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250802457609     Document Type: Article

References (22)

1. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review [see comment]. [review] [38 refs]. Am J Health System Pharm 2005;62(7):691-9
2. Morrison JC, Pollack IP. Glaucoma science and practice. Thieme: New York, 2003. p. 383
3. Allen RC. Medical management of glaucoma. In: Principles and practice of ophthalmology. 2nd edition. WB Saunders Co.: Philadelphia; 2000. p. 2898
4. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113(12):1514-7
5. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 2003;48(Suppl 1):S47-51
6. Bylund DB, Chacko DM. Characterization of alpha-2 adrenergic receptor subtypes in human ocular tissue homogenates. Invest Ophthalmol Vis Sci 1999;40(10):2299-306
7. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42(12):2849
8. Kent AR, Nussdorf JD, David R, et al. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 2001;4(108):784-7
9. Albert DM, Jakobiec FA. Principles and practice of ophthalmology. 2nd edition. WB Saunders Co.: Philadelphia; 2000. p. 2897-8
10. Barnebey HS. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol 1993;100:1083
11. Zimmerman TJ. Textbook of ocular pharmacology. Lippincott-Raven: Philadelphia; 1997, p. 250
12. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997;104(1):131-6. Published erratum appears in: Ophthalmology 1997;104(3):346
13. Katz LJ; and the Brimonidine Study Group. Brimonidine tartrate 0.2% twice daily versus timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol 1999;127(1):21-6
14. Fung AT, Reid SE, Jones MP, et al. Meta-analysis of randomized controlled trials comparing latanproast with brimonidine in the treatmet of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Opthalmol 2007;91:62-8
15. Centofanti MM. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Graefe's archive for clinical and experimental ophthalmology 2000;238:302-5
16. thoe Schwartzenberg GWS, Buys YM. Efficacy of brimonidine 0.2% as adjunvtive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology 1999;106(8):1616-20
17. Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocular Pharm Ther 2005;21(4):337-48
18. Hoyung PFJ, van Beck LM. Pharmacological therapy for glaucoma: a review. Drugs 2000;59(3):411-34
19. Hegde V, Robinson R, Dean F, et al. Drug-induced ectropion: what is best practice? Ophthalmology 2007;114(2):362-6
20. Chan K, Testa M, McClusky P. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/ timolol 0.5%. J Ocular Pharm Ther 2007;23(4):372-5
21. Al-Shahwan S, l-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology 2005;112(12):2143-8
22. Soto-Perez-de-Celis E, Skvirsky DO, Cisneros BG. Unintentional ingestion of brimonidine antiglaucoma drops: a case report and review of the literature. Pediatric Emerg Care 2007;23(9):657-8